Predictions
Nanobiotix
Start price
Target price
Perf. (%)
€8.51
11.11.21
11.11.21
€10.00
11.11.22
11.11.22
-53.17%
12.11.22
12.11.22
Could be worthwhile Investment >10% per year
Transgene S.A.
Start price
Target price
Perf. (%)
€2.43
07.11.21
07.11.21
€2.80
07.11.22
07.11.22
-20.58%
08.11.22
08.11.22
Could be worthwhile Investment >10% per year
Virbac S.A.
Start price
Target price
Perf. (%)
€401.50
07.11.21
07.11.21
€385.00
07.11.22
07.11.22
-38.36%
22.10.22
22.10.22
Could be worthwhile Investment >10% per year
Nicox S.A.
Start price
Target price
Perf. (%)
€3.19
29.09.21
29.09.21
€3.80
29.09.22
29.09.22
-46.37%
30.09.22
30.09.22
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€11.82
14.09.21
14.09.21
€30.00
14.09.22
14.09.22
-29.36%
15.09.22
15.09.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Future proof or reliable business model
Standard Investments for future growth
Inventiva SA
Start price
Target price
Perf. (%)
€11.54
10.09.21
10.09.21
€8.00
10.09.22
10.09.22
-63.65%
11.09.22
11.09.22
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€24.64
16.12.21
16.12.21
€33.00
31.12.23
31.12.23
-67.02%
07.09.22
07.09.22
Could be very worthwhile Investment >20% year
Valneva SE
Start price
Target price
Perf. (%)
€20.18
03.09.21
03.09.21
€30.00
03.09.22
03.09.22
-59.38%
03.09.22
03.09.22
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Some uniques
Higher risks for its business
Valneva SE
Start price
Target price
Perf. (%)
€13.84
25.08.21
25.08.21
-
25.08.22
25.08.22
-32.23%
26.08.22
26.08.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Valneva SE
Start price
Target price
Perf. (%)
€29.96
30.11.21
30.11.21
€35.00
30.11.22
30.11.22
-66.46%
12.08.22
12.08.22
Could be very worthwhile Investment >20% year
Valneva SE
Start price
Target price
Perf. (%)
€28.32
29.11.21
29.11.21
-
29.11.22
29.11.22
-65.32%
21.07.22
21.07.22
Revenue growth >5% per year expected
Could be very worthwhile Investment >20% year
High valuation
Growths slower than the competition
Abivax S.A.
Start price
Target price
Perf. (%)
€25.50
01.12.21
01.12.21
€28.00
01.12.22
01.12.22
-31.92%
20.05.22
20.05.22
Future proof or reliable business model
Probably not worthwhile Investment
overvalued
Very low/no dividend yield expected
Edap Tms S.A. ADR
Start price
Target price
Perf. (%)
€5.00
03.01.22
03.01.22
-
03.01.23
03.01.23
27.00%
15.05.22
15.05.22
Probably not worthwhile Investment
Valneva SE
Start price
Target price
Perf. (%)
€28.30
27.11.21
27.11.21
€28.00
27.11.22
27.11.22
-44.88%
30.03.22
30.03.22
Could be worthwhile Investment >10% per year
Very valuable balance sheet
Poxel S.A.
Start price
Target price
Perf. (%)
€3.04
20.02.22
20.02.22
€4.00
20.03.22
20.03.22
-11.39%
21.03.22
21.03.22
Could be worthwhile Investment >10% per year
Innate Pharma
Start price
Target price
Perf. (%)
€4.80
05.09.21
05.09.21
-
05.09.22
05.09.22
-47.79%
07.03.22
07.03.22
Probably not worthwhile Investment
Poxel S.A.
Start price
Target price
Perf. (%)
€4.07
15.02.22
15.02.22
€5.00
15.03.22
15.03.22
-25.36%
20.02.22
20.02.22
Could be worthwhile Investment >10% per year
Poxel S.A.
Start price
Target price
Perf. (%)
€5.37
24.11.21
24.11.21
€6.00
24.11.22
24.11.22
-24.21%
15.02.22
15.02.22
Could be worthwhile Investment >10% per year
Innate Pharma
Start price
Target price
Perf. (%)
€3.51
01.02.22
01.02.22
€4.15
01.02.23
01.02.23
-7.69%
10.02.22
10.02.22
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€15.90
23.01.22
23.01.22
-
23.01.23
23.01.23
-5.47%
06.02.22
06.02.22
Could be very worthwhile Investment >20% year
Innate Pharma
Start price
Target price
Perf. (%)
€4.12
10.01.22
10.01.22
-
10.01.23
10.01.23
-14.85%
01.02.22
01.02.22
Could be worthwhile Investment >10% per year
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€8.16
15.01.21
15.01.21
-
15.01.22
15.01.22
-63.58%
16.01.22
16.01.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group